2 Information about ribociclib

Marketing authorisation indication

2.1

Ribociclib (Kisqali, Novartis) 'in combination with an aromatase inhibitor is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist'.

Dosage in the marketing authorisation

Price

2.3

The list prices of ribociclib 200-mg tablets are:

  • £983.33 per 21-pack

  • £1,966.67 per 42-pack

  • £2,950.00 per 63-pack

    (excluding VAT; BNF online, accessed March 2025).

2.4

The company has a simple patient access scheme. This makes ribociclib available to the NHS with a discount. The size of the discount is commercial in confidence.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Novartis will be included here when guidance is published.